Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs.

ABSTRACT:

Objective

To comprehensively assess the pharmacogenomic evidence of routinely used drugs for clinical utility.

Methods

Between January 2, 2011, and May 31, 2013, we assessed 71 drugs by identifying all drug/genetic variant combinations with published clinical pharmacogenomic evidence. Literature supporting each drug/variant pair was assessed for study design and methods, outcomes, statistical significance, and clinical relevance. Proposed clinical summaries were formally scored using a modified AGREE (Appraisal of Guidelines for Research and Evaluation) II instrument, including recommendation for or against guideline implementation.

Results

Positive pharmacogenomic findings were identified for 51 of 71 cardiovascular drugs (71.8%), representing 884 unique drug/variant

SUBMITTER: Kaufman AL 

PROVIDER: S-EPMC4475352 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature